

# HPV-FASTER: broadening the scope for prevention of H

Nature Reviews Clinical Oncology

13, 119-132

DOI: [10.1038/nrclinonc.2015.146](https://doi.org/10.1038/nrclinonc.2015.146)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epidemiology and Burden of Disease Associated with HPV Infection. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 181-188.	0.8	4
2	Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID). <i>Journal of Virus Eradication</i> , 2016, 2, 187-192.	0.5	0
3	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1154-1168.	9.1	148
4	Age of human papillomavirus vaccination?. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1091-1093.	9.1	4
5	Carcinogenic human papillomavirus infection. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16086.	30.5	615
6	Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-2040: a population-based study. <i>Lancet Oncology</i> , The, 2016, 17, 1445-1452.	10.7	68
7	Prior human papillomavirus 16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: a post-hoc analysis from a randomized controlled trial. <i>International Journal of Cancer</i> , 2016, 139, 2812-2826.	5.1	74
8	Validation of Novaprep <sup>®</sup> HQ+ liquid-based cytology medium for high-risk human papillomavirus detection by hc2. <i>Infectious Agents and Cancer</i> , 2016, 11, 41.	2.6	1
9	Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting. <i>Journal of Clinical Virology</i> , 2016, 76, S29-S39.	3.1	18
10	Immunologic approaches to cancer prevention—current status, challenges, and future perspectives. <i>Seminars in Oncology</i> , 2016, 43, 161-172.	2.2	35
11	Control of HPV-associated cancers with HPV vaccination. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 6-8.	9.1	6
12	Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 379-391.	3.1	55
13	Mechanistic mathematical models: An underused platform for HPV research. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 46-49.	4.5	9
14	Psycho-social influences upon older women's decision to attend cervical screening: A review of current evidence. <i>Preventive Medicine</i> , 2017, 101, 60-66.	3.4	35
15	Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study. <i>International Journal of Cancer</i> , 2017, 141, 519-530.	5.1	11
16	HPV vaccines — A review of the first decade. <i>Gynecologic Oncology</i> , 2017, 146, 196-204.	1.4	304
17	Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology. <i>Diagnostic Cytopathology</i> , 2017, 45, 903-914.	1.0	10
19	Worldwide burden of cancer attributable to HPV by site, country and HPV type. <i>International Journal of Cancer</i> , 2017, 141, 664-670.	5.1	1,414

#	ARTICLE	IF	CITATIONS
20	Causal system modelling of cervical cancer screening. <i>Lancet Public Health, The</i> , 2017, 2, e61-e62.	10.0	1
21	Considerations for HPV primary screening in lower-middle income countries. <i>Preventive Medicine</i> , 2017, 98, 39-41.	3.4	9
22	Ten-year immune persistence and safety of the 16/18 AS04 adjuvanted vaccine in females vaccinated at 15-55 years of age. <i>Cancer Medicine</i> , 2017, 6, 2723-2731.	2.8	52
23	Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. <i>Lancet Infectious Diseases, The</i> , 2017, 17, 1293-1302.	9.1	186
24	Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point: registry-based follow-up of three cohorts from randomized trials. <i>BMJ Open</i> , 2017, 7, e015867.	1.9	67
25	Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends. <i>International Journal of Cancer</i> , 2017, 141, 1997-2001.	5.1	114
26	Optimizing secondary prevention of cervical cancer: Recent advances and future challenges. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 15-19.	2.3	39
28	Overcoming barriers in HPV vaccination and screening programs. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 4, 45-53.	4.5	41
29	<i>Pediatric Vaccines and Vaccinations.</i> , 2017, , .		1
30	HPV types in cervical cancer tissue in South Africa. <i>Medicine (United States)</i> , 2017, 96, e8752.	1.0	7
31	Natural History of HPV Infection across the Lifespan: Role of Viral Latency. <i>Viruses</i> , 2017, 9, 267.	3.3	166
32	Why Human Papillomavirus Acute Infections Matter. <i>Viruses</i> , 2017, 9, 293.	3.3	49
33	Human papillomavirus vaccination: the population impact. <i>F1000Research</i> , 2017, 6, 866.	1.6	73
34	Opportunities and challenges for human papillomavirus vaccination in cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 240-254.	28.4	224
35	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1222-1228.	6.3	12
36	Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. <i>International Journal of Cancer</i> , 2018, 143, 735-745.	5.1	124
37	Sustained Cross-protection of the Bivalent Human Papillomavirus Vaccine. <i>Journal of Infectious Diseases</i> , 2018, 217, 1515-1516.	4.0	3
38	Accelerating cervical cancer control and prevention. <i>Lancet Public Health, The</i> , 2018, 3, e6-e7.	10.0	13

#	ARTICLE	IF	CITATIONS
39	HPV16 targeted DNA vaccine expression: The role of purification. <i>Biotechnology Progress</i> , 2018, 34, 546-551.	2.6	5
40	The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 92-97.	4.4	53
41	Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. <i>Expert Review of Vaccines</i> , 2018, 17, 395-409.	4.4	19
42	Identifying populations most susceptible to get benefit from broadening the scope for prevention of cervical cancer: Example from Uruguay. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 122-127.	4.5	0
43	Options for design of real-world impact studies of single-dose vaccine schedules. <i>Vaccine</i> , 2018, 36, 4816-4822.	3.8	11
44	Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 5, 114-121.	4.5	29
45	Melatonin increases human cervical cancer HeLa cells apoptosis induced by cisplatin via inhibition of JNK/Parkin/mitophagy axis. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 1-10.	1.5	48
46	Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. <i>Vaccine</i> , 2018, 36, 5416-5423.	3.8	39
47	Cervical Cancer: Screening, Vaccination, and Preventive Strategies. , 2018, , .		0
48	Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma. <i>Infectious Agents and Cancer</i> , 2018, 13, 35.	2.6	8
49	Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. <i>Viruses</i> , 2018, 10, 729.	3.3	161
50	Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 394-424.	329.8	62,121
51	Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018, 23, 484-494.	0.6	9
52	The next generation of cervical cancer screening programs: Making the case for risk-based guidelines. <i>Current Problems in Cancer</i> , 2018, 42, 521-526.	2.0	5
53	Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. <i>The Cochrane Library</i> , 2020, 2020, CD009069.	2.8	288
54	Making <sc>HPV</sc> vaccination available to girls everywhere. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 267-276.	2.3	21
55	Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 707-714.	5.6	44
56	A Practical Guide to Gynecologic and Reproductive Health in Women Undergoing Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e331-e343.	2.0	15

#	ARTICLE	IF	CITATIONS
57	Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination—Review of Current Perspectives. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	1.3	209
58	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100184.	4.5	41
59	HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?. <i>International Journal of Infectious Diseases</i> , 2019, 88, 110-112.	3.3	13
60	(At Least) Once in Her Lifetime: Global Cervical Cancer Prevention. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 107-123.	1.9	12
61	Prevalence and determinants of cervical cancer screening with a combination of cytology and human papillomavirus testing. <i>Annals of Epidemiology</i> , 2019, 36, 40-47.	1.9	5
62	Human papillomavirus vaccination: The ESGO—EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy. <i>European Journal of Cancer</i> , 2019, 116, 21-26.	2.8	36
63	Feasibility of a combined strategy of HPV vaccination and screening in Mexico: the FASTER-Tlalpan study experience. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1986-1994.	3.3	7
64	New perspectives on screening and early detection of endometrial cancer. <i>International Journal of Cancer</i> , 2019, 145, 3194-3206.	5.1	58
65	Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. <i>Climacteric</i> , 2019, 22, 596-602.	2.4	13
66	Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany. <i>British Journal of Cancer</i> , 2019, 120, 1015-1022.	6.4	24
67	Human Papillomavirus Research: Where Should We Place Our Bets?. <i>Acta Cytologica</i> , 2019, 63, 85-96.	1.3	5
68	Opportunities to improve immune-based prevention of HPV-associated cancers. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 7, 150-153.	4.5	13
69	Gynecological Cancers—the Changing Paradigm. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 156-161.	0.7	0
70	HPV as a marker for molecular characterization in head and neck oncology: Looking for a standardization of clinical use and of detection method(s) in clinical practice. <i>Head and Neck</i> , 2019, 41, 1104-1111.	2.0	41
71	Uptake of the HPV vaccine among people with and without HIV, cisgender and transgender women and men who have sex with men and with women at two sexual health clinics in Mexico City. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 981-990.	3.3	9
72	Clinical Trials of Human Papillomavirus Vaccines. , 2020, , 299-325.		1
73	Epilogue: Looking forward to cervical cancer elimination. , 2020, , 389-402.		0
74	Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 955-963.	6.3	37

#	ARTICLE	IF	CITATIONS
75	The role of knowledge, risk perceptions, and cues to action among Iranian women concerning cervical cancer and screening: a qualitative exploration. <i>BMC Public Health</i> , 2020, 20, 1688.	2.9	7
76	Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine. <i>Frontiers in Immunology</i> , 2020, 11, 1434.	4.8	15
77	Serum and cervicovaginal IgG immune responses against $\hat{1}\pm 7$ and $\hat{1}\pm 9$ HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination. <i>PLoS ONE</i> , 2020, 15, e0233084.	2.5	3
78	Alterations of HPV-Related Biomarkers after Prophylactic HPV Vaccination. A Prospective Pilot Observational Study in Greek Women. <i>Cancers</i> , 2020, 12, 1164.	3.7	27
79	Detection of Alpha, Beta, Gamma, and Unclassified Human Papillomaviruses in Cervical Cancer Samples From Mexican Women. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 234.	3.9	15
80	Sensitivity of cervico-vaginal cytology in endometrial carcinoma: A systematic review and meta-analysis. <i>Cancer Cytopathology</i> , 2020, 128, 792-802.	2.4	23
81	HPV vaccination and cancer prevention. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 109-124.	2.8	51
82	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. <i>JAMA Oncology</i> , 2020, 6, 696.	7.1	18
83	Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?. <i>PLoS Medicine</i> , 2020, 17, e1003035.	8.4	36
84	Baseline prevalence and type distribution of Human papillomavirus in sexually active non-vaccinated adolescent girls from Argentina. <i>Revista Argentina De Microbiologia</i> , 2021, 53, 11-19.	0.7	6
85	p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. <i>Journal of the National Cancer Institute</i> , 2021, 113, 292-300.	6.3	41
86	Importance of Lifetime Sexual History on the Prevalence of Genital Human Papillomavirus (HPV) Among Unvaccinated Adults in the National Health and Nutrition Examination Surveys: Implications for Adult HPV Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 72, e272-e279.	5.8	6
87	Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 955-964.	3.3	5
88	Elimination of cervical cancer in low- and middle-income countries: Inequality of access and fragile healthcare systems. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 7-11.	2.3	23
89	High Prevalence of Cervical High-Risk Human Papillomavirus Harboring Atypical Genotypes in Human Immunodeficiency Virus -Infected and -Uninfected First-Generation Adult Immigrant Women Originating from Sub-Saharan Africa and Living in France. <i>Journal of Immigrant and Minority Health</i> , 2021, 23, 308-319.	1.6	1
90	Human Papillomavirus (HPV) Vaccines and Their Impact. , 2021, , 295-299.		0
91	A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 101, 106266.	1.8	14
92	Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 209-249.	329.8	52,977

#	ARTICLE	IF	CITATIONS
94	Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. <i>American Journal of Preventive Medicine</i> , 2021, 60, 478-487.	3.0	13
95	Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. <i>Vaccine</i> , 2021, 39, 2800-2809.	3.8	23
96	Human papillomavirus (HPV) testing for cervical cancer screening in a middle-income country: comment on a large real-world implementation study in China. <i>BMC Medicine</i> , 2021, 19, 165.	5.5	4
97	Prevalence of high-risk human papillomavirus infection among Kazakhstani women attending gynecological outpatient clinics. <i>International Journal of Infectious Diseases</i> , 2021, 109, 8-16.	3.3	14
98	Prospects for accelerated elimination of cervical cancer. <i>Preventive Medicine</i> , 2021, 153, 106827.	3.4	9
99	Successful retrieval of human papillomavirus DNA after a 4.5 year storage on FTA elute cards. <i>Journal of Virological Methods</i> , 2021, 296, 114218.	2.1	1
100	Human Papillomavirus Vaccines. , 2021, , 147-157.		0
101	Age of Acquiring Causal Human Papillomavirus (HPV) Infections: Leveraging Simulation Models to Explore the Natural History of HPV-induced Cervical Cancer. <i>Clinical Infectious Diseases</i> , 2017, 65, 893-899.	5.8	58
102	Vaccination to prevent human papillomavirus infections: From promise to practice. <i>PLoS Medicine</i> , 2017, 14, e1002325.	8.4	40
103	An update on prophylactic human papillomavirus (HPV) vaccines: a review of key literature published between September 2018 and September 2019. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2019, 28, .	0.1	2
104	Prevention and control of neoplasms associated with HPV in high-risk groups in Mexico City: The Condesa Study. <i>Salud Publica De Mexico</i> , 2018, 60, 703.	0.4	7
105	HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns. <i>Salud Publica De Mexico</i> , 2018, 60, 612.	0.4	6
106	Alternative HPV vaccination schedules in Latin America. <i>Salud Publica De Mexico</i> , 2018, 60, 693.	0.4	2
107	HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. <i>Salud Publica De Mexico</i> , 2016, 58, 211-219.	0.4	15
108	Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2339-2343.	1.2	15
110	Human Papillomavirus Vaccines. , 2017, , 127-136.		0
111	Control and Prevention in Cervical Cancer. , 2017, , 87-97.		0
112	Crossroads of Primary and Secondary Cervical Cancer Prevention Strategies in Resource-Constrained Settings. <i>Journal of Cancer Prevention &amp; Current Research</i> , 2017, 7, .	0.1	0

#	ARTICLE	IF	CITATIONS
113	Overview of Cervical and Anal Cytopathology. , 2020, , 27-41.		1
114	Human Papillomavirus Selected Properties and Related Cervical Cancer Prevention Issues. Current Pharmaceutical Design, 2020, 26, 2073-2086.	1.9	4
115	Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): 25-27 May, Marseille, France. Journal of Virus Eradication, 2016, 2, 187-92.	0.5	0
116	TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). Human Vaccines and Immunotherapeutics, 2021, 17, 4299-4327.	3.3	0
117	HPV Immunization. , 2021, , 457-466.		0
118	HPV-Impfung: Sehr effektiv " aber immer noch vernachlässigt. , 0, , .		0
119	Optimising the oil phases of aluminium hydrogel-stabilised emulsions for stable, safe and efficient vaccine adjuvant. Frontiers of Chemical Science and Engineering, 2022, , 1-12.	4.4	1
120	HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis. Journal of Gynecologic Oncology, 2022, 33, .	2.2	3
121	Cervical cancer, geographical inequalities, prevention and barriers in resource depleted countries (Review). Oncology Letters, 2022, 23, 113.	1.8	11
122	Impact of catch-up human papillomavirus vaccination on cervical cancer incidence in Kenya: A mathematical modeling evaluation of HPV vaccination strategies in the context of moderate HIV prevalence. EClinicalMedicine, 2022, 45, 101306.	7.1	11
123	The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss. Journal of the National Cancer Institute, 2022, 114, 1333-1337.	6.3	5
124	RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer. Journal of Virology, 2022, 96, .	3.4	9
125	Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Frontiers in Oncology, 0, 12, .	2.8	108
126	Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	6
127	Cervical cancer screening in low- and middle-income countries: A systematic review of economic evaluation studies. Clinics, 2022, 77, 100080.	1.5	6
129	The socioeconomic burden of a diagnosis of cervical cancer in women in rural Uganda: findings from a descriptive qualitative study. International Journal of Palliative Nursing, 2022, 28, 322-332.	0.5	4
130	Human Papillomavirus Vaccination: Past, Present and Future. Vaccines, 2022, 10, 1398.	4.4	4
131	An Overview of HPV Screening Tests to Improve Access to Cervical Cancer Screening Amongst Underserved Populations: From Development to Implementation. Risk Management and Healthcare Policy, 0, Volume 15, 1823-1830.	2.5	5



#	ARTICLE	IF	CITATIONS
132	HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage. <i>Cancer Treatment Reviews</i> , 2022, 111, 102467.	7.7	9
133	Prevalence of cervical human papillomavirus in Mexico, 2010–2017: analysis of 2.7 million women. <i>Cancer Causes and Control</i> , 0, , .	1.8	0
134	Prevention of Cervical Cancer in Low-Resource African Settings. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 771-781.	1.9	6
135	Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State. <i>Vaccines</i> , 2022, 10, 1912.	4.4	25
136	Cervical cancer in Nepal: Current screening strategies and challenges. <i>Frontiers in Public Health</i> , 0, 10, .	2.7	8
137	Human papillomavirus vaccination and cervical cancer risk. <i>BMJ, The</i> , 0, , e070115.	6.0	20
138	Updates on HPV Vaccination. <i>Diagnostics</i> , 2023, 13, 243.	2.6	14
139	Assessment of Acceptability and Determinants of Uptake and Schedule Completion of Human Papillomavirus (HPV) Vaccine by 25 to 45 Years Old Women in Slovenia. <i>Vaccines</i> , 2023, 11, 423.	4.4	2
140	Reproductive and Obstetric Outcomes after Fertility-Sparing Treatments for Cervical Cancer: Current Approach and Future Directions. <i>Journal of Clinical Medicine</i> , 2023, 12, 2614.	2.4	1
141	Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?. <i>Tumour Virus Research</i> , 2023, 16, 200263.	3.8	0
142	Perception of Women's Knowledge of and Attitudes towards Cervical Cancer and Papanicolaou Smear Screenings: A Qualitative Study in South Africa. <i>Healthcare (Switzerland)</i> , 2023, 11, 2089.	2.0	1
143	Factors associated with receiving results and attending colposcopy in patients with positive HPV screens in Mexico City. <i>Preventive Medicine Reports</i> , 2023, 35, 102347.	1.8	1
144	Prevalence, persistence, clearance and risk factors for HPV infection in rural Uyghur women in China. <i>BMC Women's Health</i> , 2023, 23, .	2.0	1
145	Acceptability of deferring the start of cervical cancer screening to age 30 for women vaccinated against human papillomavirus. <i>Preventive Medicine Reports</i> , 2023, 36, 102438.	1.8	0
148	A retrospective cohort study of human papillomavirus (HPV) genotypes in women with abnormal Pap smear cytology in Turkey. <i>Journal of Surgery and Medicine</i> , 2023, 7, 637-640.	0.1	1
150	Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic. <i>ELife</i> , 0, 12, .	6.0	2
151	A portable all-in-one microfluidic device with real-time colorimetric LAMP for HPV16 and HPV18 DNA point-of-care testing. <i>Biosensors and Bioelectronics</i> , 2024, 248, 115968.	10.1	0
152	ĐœĐµŃ,Đ¾ĐĐ¾Đ»Đ¾ĐĐŃ,ŃĐ,ŃŃ,,Ń,,ĐµĐ°Ń,ĐĐ²Đ½Đ¾ŃŃ,ŃŒ ŃĐ°ŃĐĐ,Đ½Đ,Đ½Đ³Đ° ŃĐ°Đ°Đ° Ń°ĐµĐ¹Đ°Đ, Đ¼Đ°Ń,Đ°Đ, Đ²Đ		

#	ARTICLE	IF	CITATIONS
153	Scientific approaches toward improving cervical cancer elimination strategies. International Journal of Cancer, 2024, 154, 1537-1548.	5.1	1
154	Parents' perspectives on dental team as advisors to promote <sc>HPV</sc> vaccination among Spanish adolescents. Journal of Public Health Dentistry, 0, , .	1.2	0